The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...